AMEX:VNRX

Volition Forms Texas-Based Veterinary Subsidiary and Appoints its Chief Executive Officer

AUSTIN, Texas, Aug. 8, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the recent formation of a subsidiary, Volition Veterinary Diagnostics Development LLC ("Volition Veterinary"), and the appointment of animal health expertNathan Dewsbury as its Chief ...

2019-08-08 20:30 6522

VolitionRx Limited Schedules Second Quarter 2019 Earnings Conference Call and Business Update

AUSTIN, Texas, Aug. 7, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced it will host a conference call onTuesday, August 13 at 8:30 a.m. Eastern time to discuss its financial and operating results for the second quarter of 2019 in addition to providing a business upd...

2019-08-07 20:45 6802

Volition Announces Exercise of Warrant to Purchase $4.8 Million in Common Stock

AUSTIN, Texas, July 24, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced a further strengthening of its balance sheet with an existing investor exercising the balance of its warrant to purchase$4.8 million in aggregate amount of shares of our common stock...

2019-07-25 04:05 9069

VolitionRx Limited Commences Lung Cancer Clinical Study with Fosun Long March in China

AUSTIN, Texas, July 18, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") has executed a contract under the previously announced Memorandum of Understanding, with Shanghai Fosun Long March Medical Science Co., Ltd. ("Fosun Long March") to help introduce the Nu.Q(TM) platf...

2019-07-18 20:30 11626

VolitionRx Limited Awarded an Additional $1.4 Million in Non-Dilutive Funding

AUSTIN, Texas, July 10, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has been awarded additional non-dilutive funding in the form of a non-repayable cash grant totaling approximately$1.4 million from the Walloon Region, Belgium.  To date, Agen...

2019-07-10 20:30 12829

VolitionRx Limited Announces First Quarter 2019 Financial Results and Business Update

AUSTIN, Texas, May 8, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the first quarter endedMarch 31, 2019. Volition management will host a conference call tomorrow,May 9, at 8:30 a.m. U.S. Eastern Time to dis...

2019-05-09 04:05 6389

VolitionRx Limited Executes a Contract for Clinical Trial Program in Lung Cancer

AUSTIN, Texas, May 7, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has added to its extensive clinical trial program with the execution of a contract under the previously announced Memorandum of Understanding, to conduct its first large-scale ...

2019-05-07 20:30 6484

VolitionRx Limited Schedules First Quarter 2019 Earnings Conference Call and Business Update

AUSTIN, Texas, May 6, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE American:  VNRX) today announced it will host a conference call onThursday, May 9 at 8:30 a.m. Eastern time to discuss its financial and operating results for the first quarter of 2019 in addition to providing a business update. ...

2019-05-07 04:05 6138

VolitionRx Limited Hosts Capital Markets Day at the New York Stock Exchange and Issues Company Update Report

ISNES, Belgium, April 9, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") hosted a Capital Markets Day at the New York Stock Exchange today to update interested parties on its recent progress. Volition has also issued a Company Update Report; a downloadable version of w...

2019-04-10 05:17 10210

VolitionRx Limited Signs Memorandum of Understanding with Texas A&M University for Potential Collaboration to Develop Nu.QTM Veterinary Diagnostics

ISNES, Belgium, April 9, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") has executed a nonbinding Memorandum of Understanding ("MOU") through its wholly-owned subsidiary, Belgian Volition SPRL, withTexas A&M University, a member of The Texas A&M University System. Pur...

2019-04-09 20:30 10255

VolitionRx Limited Signs Memorandum of Understanding with Fosun Long March in China

ISNES, Belgium, March 28, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") has executed a nonbinding Memorandum of Understanding ("MOU") with Shanghai Fosun Long March Medical Science Co., Ltd. ("Fosun Long March") with an expectation of negotiating and entering into a ...

2019-03-28 22:48 8975

VolitionRx Limited to Present at Conferences in March & April 2019

ISNES, Belgium, March 25, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its Executive Vice President, Investor Relations,Scott Powell, is scheduled to present at three conferences in March andApril 2019. During the conferences, Dr. Powell will ou...

2019-03-25 20:40 5551

VolitionRx Limited to Present at Conferences in the U.S. Next Week

ISNES, Belgium, March 15, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its Chief Executive Officer, Mr.Cameron Reynolds, is scheduled to present at two conferences in the U.S. next week. During the conferences, Mr. Reynolds will outline Volition...

2019-03-15 20:30 4385

VolitionRx Limited Announces Full Fiscal Year 2018 Financial Results and Business Update

ISNES, Belgium, March 13, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the full fiscal year endedDecember 31, 2018. Volition management will host a conference call tomorrow,March 14, at 8:30a.m. U.S. Eastern...

2019-03-14 04:05 5982

VolitionRx Limited Schedules Full Year 2018 Earnings Conference Call and Business Update

ISNES, Belgium, March 7, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced it will host a conference call onThursday, March 14 at 8:30 a.m. Eastern time to discuss its financial and operating results for the fourth quarter and full year 2018, in conjunction with the f...

2019-03-07 21:30 8169

VolitionRx Limited to Expand its Nu.Q(TM) Trials to Veterinary Diagnostics

ISNES, Belgium, Oct. 4, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced very encouraging preliminary results from a proof of concept study using its Nu.Q™ diagnostic test in veterinary medicine at the 10th anniversary meeting of the Belgian Technology Mi...

2018-10-04 21:00 418

VolitionRx Limited Releases Video Featuring Interviews with its Scientific Advisory Board

ISNES, Belgium, Sept. 26 2018 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition") today released a video featuring members of its Scientific Advisory Board (SAB). The video was taken at Volition's laboratories inBelgium during the last SAB meeting and features members of the SAB...

2018-09-26 21:00 290

VolitionRx Limited to Attend Multiple Conferences in September

ISNES, Belgium, Sept. 5, 2018 /PRNewswire/ -- VolitionRx Limited  (NYSE American: VNRX) today announced that its Chief Executive Officer,Cameron Reynolds and/or its Executive Vice President of Investor Relations,Scott Powell, are scheduled to attend and present at mul...

2018-09-05 20:30 394

VolitionRx Limited Announces Second Quarter 2018 Financial Results and Business Update

ISNES, Belgium, Aug. 13, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the quarter endedJune 30, 2018. Volition management will host a conference call to discuss these results and provide a further business u...

2018-08-14 04:05 721

Preliminary Data from Study Demonstrates 94% Accuracy in Detecting Aggressive Prostate Cancer

ISNES, Belgium, Aug. 13, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced preliminary data from a prospective, multi-centered Proof of Concept Study of 84 men into the utility of Volition's Nu.Q™ assays to diagnose men with high-grade prostate cancer. Vo...

2018-08-13 20:30 560
1234